ABSTRACT BACKGROUND Mortality in cardiogenic shock (CS) remains high. Early risk stratification is crucial to make adequate
therapies, such as active assist devices).
Therefore, there remains an obvious need for a risk stratification tool that is simple, easily applicable in clinical practice, and readily available directly after admission at the catheterization laboratory. Furthermore, designing clinical trials in patients with CS is challenging due to the large heterogeneity and variability of outcomes in this population of critically ill patients (3) . A severity scoring system might be useful to conduct trials with a more homogeneous patient population. Although several scores have been developed based on patient registry data and randomized clinical trials (7) (8) (9) (10) , almost all of them share certain limitations: 1) they were not validated; 2) they were derived from small studies; 3) the etiology of CS often was not restricted to AMI; and 4) the parameters used cannot be easily assessed directly in the catheterization lab. The aim of this study was to develop a simple, easy-to-use, readily available, fully validated risk score for short-term mortality prediction in the catheterization laboratory in patients with AMIrelated CS undergoing PCI enrolled in the largest randomized CS trial to date.
METHODS
The present analysis is a substudy of the randomized IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock II) trial. In this trial, intra-aortic balloon pump (IABP) support was compared with no IABP support in patients with AMI-related CS. There were no significant differences between the 2 treatment groups with respect to short-and long-term outcomes. The design of the trial and its main results have been published previously (11) (12) (13) . Briefly, 600 patients were enrolled in 37 centers in Germany and randomly allocated to either IABP support or to a control group in a 1:1 fashion. CS was defined as hypotension, pulmonary congestion, and signs of end-organ hypoperfusion. Exclusion criteria were duration of CS >12 h, cardiopulmonary resuscitation >30 min, severe cerebral deficit, mechanical causes of CS, age >90 years, absolute contraindications against IABP insertion, shock of other cause, or severe concomitant disease with life expectancy <6 months.
All patients underwent cardiac catheterization immediately after hospital admission. The primary endpoint was 30-day all-cause mortality. Patients with AMI complicated by CS who met any exclusion criterion of the IABP-SHOCK II trial were enrolled into an associated registry (n ¼ 188). The study, which was conducted according to the Declaration of Helsinki, was approved by the local ethics committees and all patients or their legal representatives gave written informed consent.
STATISTICAL ANALYSIS. The model was developed on the randomized population of the IABP-SHOCK II trial (n ¼ 600) using a stepwise multivariable Cox proportional hazards regression analysis with the forward selection technique. Unselected extensive univariable testing was performed including all database variables potentially associated with mortality. Variables significantly related to mortality in univariable testing (p < 0.10) were further examined in multivariable analysis. Herein, 6 variables remained statistically significant associated with mortality. These variables constitute the score parameters. Only patients with complete datasets for these 6 score candidate variables were considered for further testing. Patients treated conservatively (19 of 600; 3.2%), as well as patients undergoing immediate coronary artery bypass grafting (CABG) (6 of 600; 1%), were excluded from the present analysis. In 17 of 600 (2.8%) patients, CABG was performed after PCI. Of these, 4 patients had to be excluded due to missing parameters. The remaining 13 patients were included in the analysis.
Continuous variables were dichotomized. The optimal cutoff points were defined using the Youden index. The scoring system was determined by rounding the respective parameter estimates, attributing either 1 or 2 points to each variable, based on the observed hazard ratio (HR). Parameters with a rounded HR of 2 or more were assigned 2 points; those with a rounded HR below 2 were assigned 1 point. According to the score, the population was 
RESULTS
Of the 600 patients enrolled in the trial, only 480 patients with complete datasets for the selected 6 variables were included as the final cohort ( Figure 1 ). The development cohort comprised patients from the IABP-SHOCK II (Intraaortic Balloon Pump in Cardiogenic Shock) trial whereas the validation cohorts were from the IABP-SHOCK II registry and CardShock trial. In the IABP-SHOCK II trial and registry, patients with missing data with respect to the score variables were excluded. With respect to the CardShock trial cohort, only patients with cardiogenic shock due to acute coronary syndrome (ACS) undergoing primary percutaneous coronary intervention (PPCI) were included. *At admission.
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The IABP-SHOCK II Risk Score at admission, creatinine at admission, arterial blood lactate at admission, and TIMI flow grade <3 after PCI. The results of the regression analysis are shown in Table 2 . The cutoff points were determined by the Youden index as follows: age >73 years, glucose at admission >10.6 mmol/l (191 mg/dl), creatinine at admission >132.6 mmol/l (1.5 mg/dl), and arterial lactate at admission >5 mmol/l. Subsequently, the IABP-SHOCK II score was created attributing either 1 or 2 points to the variables (Central Illustration). The score has a minimum of 0 and a maximum of 9 points.
Using the score, the population was classified into 3 CI ¼ confidence interval; other abbreviations as in Table 1 .
The IABP-SHOCK II Risk Score The observed mortality rates (low vs. intermediate vs.
high) in chi-square testing were 31.1%, 63.2%, and 100%, respectively (p < 0.0001) ( Figure 3A ). Using a stepwise multivariable regression analysis, we sought to create a risk score for mortality in patients with cardiogenic shock complicating acute myocardial infarction. The scoring system was determined by rounding the respective parameter estimates, attributing per the predicted probability of 30-day mortality. Subsequently, the mean probability of predicted 30-day mortality of each quintile was plotted against the observed frequency of mortality. The first number denotes the predicted probability; the second number denotes the observed 30-day mortality.
External validation in the CardShock
The IABP-SHOCK II Risk Score Another limitation was that a certain number of patients needed to be excluded from the analyses due to missing data regarding the score variables.
However, event rates were comparable in the included and excluded sample of patients-both in the developmental and registry validation cohorts. Pöss et al.
The IABP-SHOCK II Risk Score
This finding precluded a relevant bias of our analysis.
Furthermore, both in IABP-SHOCK II and in CardShock, TIMI flow after PCI was not assessed by a core laboratory. Available data showed that TIMI flow was usually classified higher if it was investigator reported compared to core-lab assessment (19) . This might produce a certain bias with respect to the true predictive value of a "correctly" assessed TIMI flow.
However, the score will be applied in clinical routine,
where TIMI flow will be assessed by the treating physician. Therefore, the fact that TIMI flow was investigator reported is rather an advantage, as it is closer to the real-life setting. 
CONCLUSIONS

